Table 1. Baseline Characteristics of the Study Population.
| Total Cohort ( N = 163) | CAA-related ICH ( n = 60) | HTN-related ICH ( n = 103) | P value | |
|---|---|---|---|---|
| Baseline clinical characteristics | ||||
| Age, means±SD | 63.3±13.6 | 71.0±9.9 | 58.8±11.8 | ＜0.001 |
| Sex, male (%) | 100 (61.3) | 32 (53.2) | 68 (66.0) | 0.109 |
| Hypertension, n (%) | 132 (80.9) | 29 (48.3) | 103 (100) | ＜0.001 |
| Diabetes mellitus, n (%) | 27 (16.6) | 10 (16.7) | 17 (16.5) | 0.542 |
| Dyslipidemia, n (%) | 38 (23.3) | 15 (25.0) | 23 (22.3) | 0.698 |
| Atrial fibrillation, n (%) | 6 (3.9) | 4 (6.7) | 2 (1.9) | 0.194 |
| Previous stroke, n (%) | 23 (14.1) | 13 (21.7) | 10 (9.7) | 0.034 |
| Antiplatelet use , n (%) | 27 (16.6) | 12 (20.0) | 15 (14.6) | 0.300 |
| Statin use, n (%) | 15 (9.2) | 7 (11.7) | 8 (7.8) | 0.209 |
| Admission NIHSS, median (IQR) | 4 (2-6) | 2 (1-5) | 4 (2-7) | 0.001 |
| Admission GCS, median (IQR) | 15 (15-15) | 15 (15-15) | 15 (15-15) | 0.319 |
| Hematoma volume, means±SD | 9.4±10.4 | 12.4±13.2 | 7.6±7.9 | 0.004 |
| Imaging characteristics | ||||
| Lacunes, n (%) | 26 (16.0) | 7 (11.7) | 19 (18.4) | 0.254 |
| CMBs, n (%) | 65 (39.9) | 22 (36.2) | 43 (41.7) | 0.523 |
| 1 | 28 (17.2) | 13 (21.7) | 15 (14.6) | 0.246 |
| 2~4 | 28 (17.2) | 7 (11.7) | 21 (20.4) | 0.155 |
| ≥ 5 | 9 (5.5) | 2 (3.3) | 7 (6.8) | 0.488 |
| lobar | 16 (9.8) | 16 (26.7) | 0 (0) | ＜0.001 |
| deep | 39 (23.9) | 0 (0) | 39 (37.9) | ＜0.001 |
| ＞ 20 CSO-EPVS, n (%) | 34 (20.8) | 23 (38.3) | 11 (10.7) | ＜0.001 |
| ＞ 20 BG-EPVS, n (%) | 18 (11.0) | 5 (8.3) | 13 (12.6) | 0.400 |
| WMHs, n (%) | 122 (74.8) | 46 (76.7) | 76 (73.8) | 0.683 |
| 1-2 | 37 (22.7) | 8 (13.3) | 29 (28.2) | 0.029 |
| 3-4 | 48 (29.4) | 18 (30.0) | 30 (29.1) | 0.906 |
| 5-6 | 37 (22.7) | 20 (33.3) | 17 (16.5) | 0.013 |
| cSS, n (%) | 11 (6.7) | 9 (15.0) | 2 (1.9) | 0.002 |
| Disseminated cSS | 7 (4.3) | 6 (10.0) | 1 (1.0) | 0.006 |
| Focal cSS | 4 (2.5) | 3 (5.0) | 1 (1.0) | 0.109 |
| The original SVD score, median (IQR) | 1 (0-2) | 1 (1-2) | 1 (0-2) | 0.570 |
| The modified SVD score, median (IQR) | 1 (1-3) | 1 (1-3) | 1 (0-2) | 0.567 |
| The refined SVD score, median (IQR) | 1 (0-2) | 1 (0-2) | 1 (0-2) | 0.822 |
| The CAA-SVD score, median (IQR) | 1 (0-1) | 1 (0-2) | 0 (0-1) | ＜0.001 |
| Total number of SVD markers, median (IQR) | 1 (1-2) | 1 (1-2) | 1 (1-2) | 0.779 |
| Recurrent stroke | 21 (12.9) | 8 (13.3) | 13 (12.6) | 0.975 |
Abbreviation: HTN = Hypertension; CAA = Cerebral amyloid angiopathy; ICH = Intracerebral Hemorrhage; NIHSS = National Institutes of Health Stroke Scale; GCS = Glasgow Coma Scale; cSS = Cortical Superficial Siderosis; CMBs = Cerebral Microbleeds; WMHs = White Matter Hyperintensities; EPVS = Enlarged Perivascular Spaces; CSO = Centrum Semiovale ; BG = Basal Ganglia; SVD = Small Vessel Disease; Results are expressed as numbers (column %), means (SD) or medians (interquartile range) as appropriate.